Oramed Pharmaceuticals Inc - Asset Resilience Ratio

Latest as of September 2025: 37.42%

Oramed Pharmaceuticals Inc (ORMP) has an Asset Resilience Ratio of 37.42% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Oramed Pharmaceuticals Inc (ORMP) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets

$82.51 Million

Cash + Short-term Investments

Total Assets

$220.49 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2008–2024)

This chart shows how Oramed Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See Oramed Pharmaceuticals Inc (ORMP) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Oramed Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ORMP market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$82.51 Million	37.42%
Total Liquid Assets	$82.51 Million	37.42%

Asset Resilience Insights

Very High Liquidity: Oramed Pharmaceuticals Inc maintains exceptional liquid asset reserves at 37.42% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Oramed Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio

Compare Oramed Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Fortress Biotech Inc NASDAQ:FBIO	Biotechnology	11.59%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Apellis Pharmaceuticals Inc NASDAQ:APLS	Biotechnology	0.58%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
BioArctic AB (publ) ST:BIOA-B	Biotechnology	72.35%
Chengzhi Shareholding Co Ltd SHE:000990	Biotechnology	6.73%

Annual Asset Resilience Ratio for Oramed Pharmaceuticals Inc (2008–2024)

The table below shows the annual Asset Resilience Ratio data for Oramed Pharmaceuticals Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	56.36%	$87.51 Million	$155.28 Million	-13.01pp
2023-12-31	69.37%	$152.99 Million	$220.55 Million	-1.94pp
2022-12-31	71.30%	$115.26 Million	$161.64 Million	+58.10pp
2021-12-31	13.20%	$16.89 Million	$128.00 Million	-32.96pp
2020-12-31	46.16%	$20.60 Million	$44.63 Million	-37.36pp
2019-12-31	83.53%	$28.95 Million	$34.66 Million	+29.80pp
2018-12-31	53.73%	$25.47 Million	$47.40 Million	+12.01pp
2017-12-31	41.73%	$16.15 Million	$38.71 Million	-21.57pp
2016-12-31	63.29%	$27.11 Million	$42.83 Million	+10.11pp
2015-12-31	53.18%	$14.02 Million	$26.35 Million	-36.39pp
2014-12-31	89.57%	$19.53 Million	$21.80 Million	+17.94pp
2013-12-31	71.63%	$6.20 Million	$8.66 Million	+67.84pp
2012-12-31	3.78%	$200.31K	$5.29 Million	-5.11pp
2011-12-31	8.89%	$384.56K	$4.33 Million	+2.00pp
2010-12-31	6.89%	$100.00K	$1.45 Million	-23.77pp
2009-12-31	30.66%	$1.00 Million	$3.26 Million	-18.88pp
2008-12-31	49.54%	$2.73 Million	$5.51 Million	--

pp = percentage points

About Oramed Pharmaceuticals Inc

NASDAQ:ORMP USA Biotechnology

Market Cap

$158.41 Million

Market Cap Rank

#18203 Global

#4045 in USA

Share Price

$3.98

Change (1 day)

+2.58%

52-Week Range

$2.06 - $4.11

All Time High

$29.75